Nilesh Patel

Director/Board Member at Cellanyx Diagnostics LLC

Consumer Services

Health Technology

Profile

Nilesh Patel is currently working as a Director at Cellanyx Diagnostics LLC.
He completed his undergraduate degree from Indian Institute of Technology Bombay and his MBA from Columbia Business School.

Nilesh Patel active positions

Companies	Position	Start
Cellanyx Diagnostics LLC Cellanyx Diagnostics LLC Medical SpecialtiesHealth Technology Cellanyx Diagnostics LLC is a company that is developing a cancer testing platform to aid clinical decision-making. The company is based in Beverly, MA and was founded by Ashok Chander and Michael Manak. The company's technology provides quantitative assessments of individual cancer cells in biopsy samples using multiple biochemical and biophysical markers of tumor aggressiveness and metastatic potential. The company has demonstrated clinical proof-of-concept with their lead test in development, which aims to improve risk stratification in men with prostate cancer.	Director/Board Member	2021-01-18

All active positions of Nilesh Patel

Training of Nilesh Patel

Columbia Business School	Masters Business Admin
Indian Institute of Technology Bombay	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Nilesh Patel's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Cellanyx Diagnostics LLC Cellanyx Diagnostics LLC Medical SpecialtiesHealth Technology Cellanyx Diagnostics LLC is a company that is developing a cancer testing platform to aid clinical decision-making. The company is based in Beverly, MA and was founded by Ashok Chander and Michael Manak. The company's technology provides quantitative assessments of individual cancer cells in biopsy samples using multiple biochemical and biophysical markers of tumor aggressiveness and metastatic potential. The company has demonstrated clinical proof-of-concept with their lead test in development, which aims to improve risk stratification in men with prostate cancer.	Health Technology